Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rich Pharmaceuticals has extended its agreement with Theradex Systems to manage its clinical sites in the US.
Subscribe to our email newsletter
Through this continued partnership, Theradex will lead the Company in commencing its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients in the United States.
"We selected Theradex to manage our clinical sites in the United States, due to Theradex’s invaluable assistance in finalizing the Investigational New Drug Application (IND #124642) with the U.S. FDA for Rich’s lead drug RP-323 in patients with AML," said Ben Chang, CEO of Rich Pharmaceuticals.
"The expansion of our team, through our collaboration with Theradex, should allow us to advance the RP-323 program as efficiently and quickly as possible to start the clinical trials in the United States."